BioHarvest Sciences (BHST) Expected to Release Quarterly Earnings on Tuesday

by · The Markets Daily

BioHarvest Sciences (NASDAQ:BHST – Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect BioHarvest Sciences to announce earnings of ($0.13) per share and revenue of $9.4510 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

BioHarvest Sciences (NASDAQ:BHST – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $8.50 million. BioHarvest Sciences had a negative net margin of 32.54% and a negative return on equity of 76.03%. On average, analysts expect BioHarvest Sciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

BioHarvest Sciences Trading Up 2.5%

BHST stock traded up $0.06 during trading on Tuesday, hitting $2.21. The company had a trading volume of 21,778 shares, compared to its average volume of 33,144. BioHarvest Sciences has a 52-week low of $1.82 and a 52-week high of $12.80. The company has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $3.91. The firm has a market capitalization of $43.46 million, a P/E ratio of -3.75 and a beta of 0.98. The company has a quick ratio of 2.44, a current ratio of 2.96 and a debt-to-equity ratio of 0.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of BioHarvest Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

View Our Latest Analysis on BHST

Institutional Investors Weigh In On BioHarvest Sciences

Hedge funds have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in BioHarvest Sciences during the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new stake in BioHarvest Sciences during the fourth quarter worth $173,000. Quadrature Capital Ltd bought a new stake in BioHarvest Sciences during the 4th quarter valued at $140,000. Osaic Holdings Inc. increased its holdings in shares of BioHarvest Sciences by 5,510.4% in the 4th quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock valued at $183,000 after acquiring an additional 34,605 shares during the period. Finally, Evercore Wealth Management LLC purchased a new position in shares of BioHarvest Sciences in the 4th quarter valued at $724,000.

About BioHarvest Sciences

(Get Free Report)

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

Featured Stories